Cantor A - Search Results

1

Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W. Antonia SJ, et al. Among authors: cantor a. J Urol. 2002 May;167(5):1995-2000. J Urol. 2002. PMID: 11956426 Clinical Trial.

2

Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.

Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ. Fishman M, et al. Among authors: cantor a. J Immunother. 2008 Jan;31(1):72-80. doi: 10.1097/CJI.0b013e31815ba792. J Immunother. 2008. PMID: 18157014 Clinical Trial.

3

Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation.

Diaz JI, Mora LB, Austin PF, Muro-Cacho CA, Cantor AB, Nicosia SV, Pow-Sang JM. Diaz JI, et al. Among authors: cantor ab. Urology. 1999 May;53(5):931-8. doi: 10.1016/s0090-4295(98)00625-6. Urology. 1999. PMID: 10223486

4

A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.

Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ. Dessureault S, et al. Among authors: cantor a. Ann Surg Oncol. 2007 Feb;14(2):869-84. doi: 10.1245/s10434-006-9196-4. Epub 2006 Nov 14. Ann Surg Oncol. 2007. PMID: 17103257 Clinical Trial.

5

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Friberg M, et al. Among authors: cantor a. Int J Cancer. 2002 Sep 10;101(2):151-5. doi: 10.1002/ijc.10645. Int J Cancer. 2002. PMID: 12209992

6

Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Mora LB, et al. Among authors: cantor a. Cancer Res. 2002 Nov 15;62(22):6659-66. Cancer Res. 2002. PMID: 12438264

7

Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Fishman MN, et al. Among authors: cantor a. Clin Cancer Res. 2006 Jan 15;12(2):523-8. doi: 10.1158/1078-0432.CCR-05-0928. Clin Cancer Res. 2006. PMID: 16428495 Clinical Trial.

8

Treatment decision-making strategies and influences in patients with localized prostate carcinoma.

Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen PB. Gwede CK, et al. Among authors: cantor a. Cancer. 2005 Oct 1;104(7):1381-90. doi: 10.1002/cncr.21330. Cancer. 2005. PMID: 16080181 Free article.

9

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. Simon GR, et al. Among authors: cantor a. Mol Cancer Ther. 2006 Aug;5(8):2130-7. doi: 10.1158/1535-7163.MCT-06-0034. Mol Cancer Ther. 2006. PMID: 16928835 Clinical Trial.

10

Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience.

Torres-Roca JF, Cantor AB, Shukla S, Montejo ME, Friedland J, Seigne JD, Heysek R, Pow-Sang J. Torres-Roca JF, et al. Urol Oncol. 2006 Sep-Oct;24(5):384-90. doi: 10.1016/j.urolonc.2005.12.003. Urol Oncol. 2006. PMID: 16962486

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

571 results

Search Page

Filters